PDCD1 and neoplasm: Hence, PD1 inhibitors could potentially activate a larger proportion of lymphocytes overall, while PDL1 inhibitors may primarily activate lymphocytes at the tumor site, where PDL1 expression is significantly higher than in the graft (23).